Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selepressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 8/20 | 0.82 |
| ▸ | OXTR | P30559 | 12/20 | 0.82 |
| ▸ | AVPR1B | P47901 | 8/20 | 0.82 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selepressin SCHEMBL19712231 | 1.00 | OXTR (0.82) | OXTRAVPR1AAVPR1BAVPR2 | |
| Selepressin SCHEMBL28487360 | 1.00 | OXTR (0.82) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15511399 | 0.89 | AVPR1A (0.78) | OXTRAVPR1AAVPR1BAVPR2 | |
| Argiprestocin SCHEMBL1230427 | 0.89 | OXTR (0.84) | OXTRAVPR1AAVPR1BAVPR2 | |
| SCHEMBL15511015 | 0.88 | OXTR (0.86) | OXTRAVPR1AAVPR1BAVPR2 | |
| Vasotocin SCHEMBL15511393 | 0.86 | OXTR (0.86) | OXTRAVPR1AAVPR1BAVPR2 | |
| Argiprestocin SCHEMBL30424966 | 0.86 | OXTR (0.86) | OXTRAVPR1AAVPR1BAVPR2 | |
| Vasotocin SCHEMBL15511347 | 0.86 | OXTR (0.86) | OXTRAVPR1AAVPR1BAVPR2 | |
| Vasotocin SCHEMBL13331 | 0.86 | OXTR (0.86) | OXTRAVPR1AAVPR1BAVPR2 | |
| Felypressin SCHEMBL1650172 | 0.86 | AVPR1A (0.82) | OXTRAVPR1AAVPR1BAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| US-12533321-B2 | Polypeptide formulations for oral delivery | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2026-01-27 | — | — | US | claimed |
| EP-4633737-A1 | USES OF AVPR1A AGONISTS | Viage Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| EP-4601623-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2025-08-20 | — | — | EP | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2024130011-A1 | USES OF AVPR1A AGONISTS | VIAGE THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | claimed |
| WO-2024079739-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-20240122860-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| US-20240122847-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | US | claimed |
| WO-2024079738-A1 | ORAL POLYPEPTIDE FORMULATIONS | Bhami's Research Laboratory, Pvt. Ltd. (IN) | 2024-04-18 | — | — | WO | claimed |
| US-11931329-B2 | Compositions and methods for treating anxiety-related disorders | YAMO PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| CN-111057140-B | Selepress purification method | 深圳市健元医药科技有限公司 | 2023-06-13 | — | — | CN | claimed |
| US-20230040681-A1 | COMPOSITIONS AND METHODS FOR TREATING ANXIETY-RELATED DISORDERS | YAMO PHARMACEUTICALS LLC (US) | 2023-02-09 | — | — | US | claimed |
| US-11446268-B2 | Compositions and methods for treating anxiety-related disorders | YAMO PHARMACEUTICALS LLC (US) | 2022-09-20 | — | — | US | claimed |
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | disclosed |
| US-20220008499-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING SEPSIS | FERRING B.V. (NL) | 2022-01-13 | — | — | US | disclosed |
| US-20190328887-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | UNIVERSITÉ DE STRASBOURG (FR) | 2019-10-31 | — | — | US | disclosed |
| EP-3257863-A1 | FLOUROUS METABOLICALLY STABLE PEPTIDE ANALOGS | Université de Strasbourg (FR) | 2017-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624002-B2 | Dimers for use in synthesis of peptidomimetics | GLUL, ARGLU1, ASNS | AVPR1A 1781/4885OXTR 467/4885AVPR1B 2286/4885 |
| US-20190328887-A1 | METABOLICALLY STABLE PEPTIDE ANALOGS | GPR119, GLP1R, GRPR | AVPR1A 134/4885OXTR 895/4885AVPR1B 108/4885 |
| US-12533321-B2 | Polypeptide formulations for oral delivery | PTMS, IAPP, IGF1R | AVPR1A 3919/4885OXTR 668/4885AVPR1B 3506/4885 |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | GLP1R, TTR, IAPP | AVPR1A 1654/4885OXTR 427/4885AVPR1B 1406/4885 |
| US-20220008499-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING SEPSIS | SELP, SERPINA6, ELANE | AVPR1A 655/4885OXTR 1596/4885AVPR1B 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.